NXGL NEXGEL INC

NEXGEL to Participate in Upcoming Investor Conferences in October 2022

NEXGEL to Participate in Upcoming Investor Conferences in October 2022

LANGHORNE, Pa., Oct. 04, 2022 (GLOBE NEWSWIRE) -- (“NEXGEL” or the “Company”) (NASDAQ: NXGL, NXGLW), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced that Adam Levy, CEO, will participate at the Dawson James Securities 7th Annual Small Cap Growth Conference in Jupiter, Florida and the LD Micro Main Event XV Conference in Los Angeles, California in October 2022.

Dawson James Securities 7th Annual Small Cap Growth Conference

Date: Wednesday, October 12th, 2022

Time: Wednesday, October 12th at 5:00 P.M. ET

Location: Wyndham Grand Hotel at Jupiter, Florida

To attend, please contact your Dawson James representative.

LD Micro Main Event XV

Date: Tuesday, October 25th – Wednesday, October 27th, 2022

Time: Wednesday, October 26th at 8:30 A.M. PT

Location: Luxe Sunset Boulevard Hotel at Los Angeles, California

To attend, register .

If you would like to book 1x1 investor meetings with NEXGEL, please contact your Dawson James representative, LD Micro representative or send an email to .

About NEXGEL, INC.

NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. Alongside its strategic partners, NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.

Investor Contacts:

Valter Pinto, Managing Director

KCSA Strategic Communications

212.896.1254

Media Contacts:

Raquel Cona

KCSA Strategic Communications

212.896.1204



EN
04/10/2022

Underlying

NXGLNEXGEL INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NEXGEL INC

 PRESS RELEASE
Free
NXGL NEXGEL INC

NEXGEL Signs Definitive Agreement to License and Acquire Transformativ...

NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products Transaction expected to approximately triple NEXGEL’s annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding ...

14m 1 EN
 PRESS RELEASE
Free
NXGL NEXGEL INC

NEXGEL Announces Financing of $1.797 Million Relating to an Acquisitio...

NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence LANGHORNE, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the financing of $1.797 million relating to a potential acquisition targeted for the first quarter of 2026. The potential acqu...

February 10, 2026 1 EN
 PRESS RELEASE
Free
NXGL NEXGEL INC

NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis ...

NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis Holdings, LLC and Appoints Him as Board Observer and Strategic Advisor LANGHORNE, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that NexGelRx, the Company’s previously announced spin-off of select drug delivery application assets, has received strategic investments from Eric ...

December 16, 2025 1 EN
 PRESS RELEASE
Free
NXGL NEXGEL INC

NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx

NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx up to $8 million of capital investment in spin-off NEXGEL will also receive a 5% global royalty in perpetuity on products sold using its drug delivery technology LANGHORNE, Pa., Dec. 11, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applica...

December 11, 2025 1 EN
 PRESS RELEASE
Free
NXGL NEXGEL INC

NEXGEL Reports Third Quarter 2025 Financial Results

NEXGEL Reports Third Quarter 2025 Financial Results LANGHORNE, Pa., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its third quarter 2025 financial results for the period ending September 30, 2025. Third Quarter 2025 Financial Highlights: Net Revenue was $2.93 million, compared to $2.94 million in Q3 2024 and $2.88 million in Q2 2025.Gross Profit w...

November 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch